Vaccination strategies have long been pivotal in combating infectious diseases, significantly reducing their global impact. Despite these successes, there remains a pressing need to enhance existing vaccine platforms and develop innovative delivery systems to address emerging challenges. Current vaccines often fall short in inducing robust mucosal and cell-mediated immunity, providing comprehensive protection against new and re-emerging strains, and broadening the scope of immunity across different genotypes and subtypes. Recent studies have highlighted the potential of engineered protein scaffolds and nanostructures as promising platforms for vaccine development. These novel approaches not only hold promise for infectious disease control but also offer potential applications in cancer regulation, drug addiction prophylaxis, and treatment of protein misfolding diseases like Parkinson's and Alzheimer's. However, there is still much to explore regarding the optimization of these platforms, particularly in terms of antigen delivery, adjuvant integration, and immune response modulation.
This research topic aims to advance the field of nanovaccines by exploring the integration of protein scaffolds and nanosized antigen delivery platforms. The primary objectives include investigating the co-delivery of antigens and adjuvants, enhancing antigen uptake and activation of antigen-presenting cells (APCs), and modulating innate and adaptive immune responses. By addressing these objectives, the research seeks to transform traditional vaccine approaches, moving from whole pathogen-based vaccines to subunit vaccines that offer improved safety and efficacy.
To gather further insights in the realm of engineered protein scaffolds and nanovaccines, we welcome articles addressing, but not limited to, the following themes:
- The role of protein scaffolds and nanosized platforms in delivering multiple antigens or antigen/adjuvant combinations.
- Co-delivery of TLR agonists with core antigen nano-vehicles to enhance T cell responses and IgG antibody production.
- Potential of nanovaccines in co-delivering immunoadjuvants with cancer-associated antigens to induce anti-tumor effects.
- Modifications of nanoparticles to target professional APCs for heightened immune responses.
- Strategic inputs from the immunological field to contribute to a disease-free world.
Vaccination strategies have long been pivotal in combating infectious diseases, significantly reducing their global impact. Despite these successes, there remains a pressing need to enhance existing vaccine platforms and develop innovative delivery systems to address emerging challenges. Current vaccines often fall short in inducing robust mucosal and cell-mediated immunity, providing comprehensive protection against new and re-emerging strains, and broadening the scope of immunity across different genotypes and subtypes. Recent studies have highlighted the potential of engineered protein scaffolds and nanostructures as promising platforms for vaccine development. These novel approaches not only hold promise for infectious disease control but also offer potential applications in cancer regulation, drug addiction prophylaxis, and treatment of protein misfolding diseases like Parkinson's and Alzheimer's. However, there is still much to explore regarding the optimization of these platforms, particularly in terms of antigen delivery, adjuvant integration, and immune response modulation.
This research topic aims to advance the field of nanovaccines by exploring the integration of protein scaffolds and nanosized antigen delivery platforms. The primary objectives include investigating the co-delivery of antigens and adjuvants, enhancing antigen uptake and activation of antigen-presenting cells (APCs), and modulating innate and adaptive immune responses. By addressing these objectives, the research seeks to transform traditional vaccine approaches, moving from whole pathogen-based vaccines to subunit vaccines that offer improved safety and efficacy.
To gather further insights in the realm of engineered protein scaffolds and nanovaccines, we welcome articles addressing, but not limited to, the following themes:
- The role of protein scaffolds and nanosized platforms in delivering multiple antigens or antigen/adjuvant combinations.
- Co-delivery of TLR agonists with core antigen nano-vehicles to enhance T cell responses and IgG antibody production.
- Potential of nanovaccines in co-delivering immunoadjuvants with cancer-associated antigens to induce anti-tumor effects.
- Modifications of nanoparticles to target professional APCs for heightened immune responses.
- Strategic inputs from the immunological field to contribute to a disease-free world.